Prelude Capital Management’s Moderna MRNA Stock Holding History

Prelude Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,300	Closed	-$413K	–	1353
2022 Q4	$413K	Buy	+2,300	New	+$376K	0.02%	641
2022 Q3	–	Sell	-4,400	Closed	-$629K	–	1800
2022 Q2	$629K	Sell	4,400 -100	-2%	-$14.3K	0.02%	693
2022 Q1	$775K	Buy	4,500 +100	+2%	+$16.8K	0.02%	683
2021 Q4	$1.12M	Sell	4,400 -1,200	-21%	-$351K	0.03%	555
2021 Q3	$2.15M	Buy	+5,600	New	+$2.07M	0.06%	277
2020 Q4	–	Sell	-400	Closed	-$28K	–	1722
2020 Q3	$28K	Sell	400 -4,000	-91%	-$279K	﹤0.01%	1272
2020 Q2	$283K	Buy	4,400 +2,900	+193%	+$159K	0.02%	631
2020 Q1	$45K	Buy	+1,500	New	+$34.5K	﹤0.01%	781

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Prelude Capital Management's MRNA Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Moderna (MRNA) in Q2 2026: 6,725 shares worth $471K. The stake represents 0.03% of the portfolio and ranks #552 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in MRNA as recently as Q4 2025.

Prelude Capital Management first reported a position in MRNA in Q4 2018 and has held it in 8 quarters since. The position peaked at $1.03M in Q4 2020. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Prelude Capital Management held 6,725 shares of Moderna worth $471K as of Q2 2026.
Moderna was a new Prelude Capital Management position in Q2 2026.
Moderna made up 0.03% of Prelude Capital Management's portfolio in Q2 2026, its #552 holding.
Prelude Capital Management first reported a position in Moderna in Q4 2018 and has held it in 8 quarters since.
Prelude Capital Management's Moderna position peaked at $1.03M in Q4 2020.
783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.